Finally, Morgan Stanley reduced their target price on Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. 10 Stocks to Sell NOW!
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.") (NYSE:BHVN) concerning possible ...
NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
On Wednesday, H.C. Wainwright reaffirmed a Buy rating and a price target of $54.00 on Biohaven Pharmaceutical (TADAWUL:2070) ...
On Monday, Piper Sandler reiterated its Overweight rating and $76.00 price target on Biohaven Pharmaceutical (TADAWUL:2070) ...
GlobalData on MSN2d
Scholar Rock SMA drug shows muscle function benefitScholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal ...
The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback